Antibody-drug conjugate αEGFR-E-P125A reduces triple-negative breast cancer vasculogenic mimicry, motility, and metastasis through inhibition of EGFR, integrin, and FAK/STAT3 signaling
Article in Cancer Research Communications (March 2024)
The most recent citing publications are shown below. View all 6 publications that cite this research output on Dimensions.
Nano-targeting vascular remodeling in cancer: Recent developments and future directions
Article in Seminars in Cancer Biology (March 2022)
Single-Cell Proteomic Profiling Identifies Nanoparticle Enhanced Therapy for Triple Negative Breast Cancer Stem Cells
Article in Cells (October 2021)